Extended Data Fig. 7: Epitope mapping deconvoluting neoantigen specific T cell responses.
From: Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial
a, IFNγ and TNFα positive CD8+ and CD4+ T cells at baseline to C5D1 for patient GU002. Data is normalized to MOG. b, Representative flow cytometry plots for patient GU002. Percent of CD8+ and CD4+ T cell responsive OLPs for c, GU002 (N = 27 OLPs) or d, all evaluated patients. N = 5 patients, N = 141 OLPs. Peptide (Pep), overlapping peptide (OLP), myelin-oligodendrocyte glycoprotein (MOG).
